The combination of tyrosine kinase inhibitors or VEGF inhibitors with immune checkpoint inhibitors can modulate the immune microenvironment by enhancing dendritic cells (DCs) and cytotoxic T lymphocytes, while inhibiting tumor-associated macrophages (TAMs), regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs). This evidence concerns the gene VEGFA and neoplasm.